Skip to main content
Erschienen in: Der Urologe 7/2015

01.07.2015 | Uroradiologie | Leitthema

Positronenemissionstomographie bei urologischen Tumorerkrankungen

verfasst von: PD Dr. T. Maurer, H. Kübler, J.E. Gschwend, M. Eiber

Erschienen in: Die Urologie | Ausgabe 7/2015

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Positronenemissionstomograpie (PET) wird bei urologischen Tumorentitäten seit vielen Jahren verwendet. Hierbei kommen verschiedene Tracersubstanzen zum Einsatz, die metabolische Informationen anzeigen oder auf einem direkten Nachweis molekularer Zielstrukturen beruhen. Während sie im Staging des Seminoms in Form der 18F-Fluordeoxyglukose- (18F-FDG-)PET als Standardverfahren Einzug in die Leitlinien gefunden haben, ist die PET aufgrund Ermangelung spezifischer Tracer bei Nierentumoren in der Routine bisher nicht etabliert. Trotz anfänglicher Euphorie scheint die PET mit 18F-FDG oder cholinbasierten Tracern auch beim Urothelkarzinom der Blase meist keinen relevanten diagnostischen Mehrwert zu erbringen und sollte daher hier mit Zurückhaltung bzw. nur im Rahmen von Studien Anwendung finden. Beim Prostatakarzinom dagegen zeichnet sich mit Hilfe neuer Tracer, die beispielsweise das prostataspezifische Membranantigen (PSMA) als Zielstruktur haben, eine Trendwende in der bisherigen Diagnostik ab. Hier scheint sich die „68Ga-PSMA-PET“ als zukünftige Standarddiagnostik zu etablieren.
Literatur
1.
Zurück zum Zitat Afshar-Oromieh A, Avtzi E, Giesel FL et al (2015) The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42:197–209PubMedCentralCrossRefPubMed Afshar-Oromieh A, Avtzi E, Giesel FL et al (2015) The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42:197–209PubMedCentralCrossRefPubMed
2.
Zurück zum Zitat Afshar-Oromieh A, Haberkorn U, Eder M et al (2012) [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur J Nucl Med Mol Imaging 39:1085–1086CrossRefPubMed Afshar-Oromieh A, Haberkorn U, Eder M et al (2012) [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur J Nucl Med Mol Imaging 39:1085–1086CrossRefPubMed
3.
Zurück zum Zitat Afshar-Oromieh A, Zechmann CM, Malcher A et al (2014) Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 41:11–20PubMedCentralCrossRefPubMed Afshar-Oromieh A, Zechmann CM, Malcher A et al (2014) Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 41:11–20PubMedCentralCrossRefPubMed
4.
Zurück zum Zitat Albers P, Albrecht W, Algaba F et al (2011) EAU guidelines on testicular cancer: 2011 update. Eur Urol 60:304–319CrossRefPubMed Albers P, Albrecht W, Algaba F et al (2011) EAU guidelines on testicular cancer: 2011 update. Eur Urol 60:304–319CrossRefPubMed
5.
Zurück zum Zitat AWMF (2014) Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms. AWMF, Düsseldorf AWMF (2014) Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms. AWMF, Düsseldorf
6.
Zurück zum Zitat Bandari RP, Jiang Z, Reynolds TS et al (2014) Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7–14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer. Nucl Med Biol 41:355–363PubMedCentralCrossRefPubMed Bandari RP, Jiang Z, Reynolds TS et al (2014) Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7–14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer. Nucl Med Biol 41:355–363PubMedCentralCrossRefPubMed
7.
Zurück zum Zitat Banerjee SR, Pullambhatla M, Foss CA et al (2014) (6)(4)Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer. J Med Chem 57:2657–2669PubMedCentralCrossRefPubMed Banerjee SR, Pullambhatla M, Foss CA et al (2014) (6)(4)Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer. J Med Chem 57:2657–2669PubMedCentralCrossRefPubMed
8.
Zurück zum Zitat Becherer A, De Santis M, Karanikas G et al (2005) FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals. Eur J Radiol 54:284–288CrossRefPubMed Becherer A, De Santis M, Karanikas G et al (2005) FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals. Eur J Radiol 54:284–288CrossRefPubMed
9.
Zurück zum Zitat Bertolini R, Goepfert C, Andrieu T et al (2015) 18F-RB390: innovative ligand for imaging the T877A androgen receptor mutant in prostate cancer via positron emission tomography (PET). Prostate 75:348–359CrossRefPubMed Bertolini R, Goepfert C, Andrieu T et al (2015) 18F-RB390: innovative ligand for imaging the T877A androgen receptor mutant in prostate cancer via positron emission tomography (PET). Prostate 75:348–359CrossRefPubMed
10.
Zurück zum Zitat Brogsitter C, Zophel K, Kotzerke J (2013) 18F-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients. Eur J Nucl Med Mol Imaging 40(Suppl 1):18–27CrossRef Brogsitter C, Zophel K, Kotzerke J (2013) 18F-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients. Eur J Nucl Med Mol Imaging 40(Suppl 1):18–27CrossRef
11.
Zurück zum Zitat Brunocilla E, Ceci F, Schiavina R et al (2014) Diagnostic accuracy of (11)C-choline PET/CT in preoperative lymph node staging of bladder cancer: a systematic comparison with contrast-enhanced CT and histologic findings. Clin Nucl Med 39:308–312CrossRef Brunocilla E, Ceci F, Schiavina R et al (2014) Diagnostic accuracy of (11)C-choline PET/CT in preoperative lymph node staging of bladder cancer: a systematic comparison with contrast-enhanced CT and histologic findings. Clin Nucl Med 39:308–312CrossRef
12.
Zurück zum Zitat Buchegger F, Garibotto V, Zilli T et al (2014) First imaging results of an intraindividual comparison of (11)C-acetate and (18)F-fluorocholine PET/CT in patients with prostate cancer at early biochemical first or second relapse after prostatectomy or radiotherapy. Eur J Nucl Med Mol Imaging 41:68–78CrossRefPubMed Buchegger F, Garibotto V, Zilli T et al (2014) First imaging results of an intraindividual comparison of (11)C-acetate and (18)F-fluorocholine PET/CT in patients with prostate cancer at early biochemical first or second relapse after prostatectomy or radiotherapy. Eur J Nucl Med Mol Imaging 41:68–78CrossRefPubMed
13.
Zurück zum Zitat Bundschuh RA, Wendl CM, Weirich G et al (2013) Tumour volume delineation in prostate cancer assessed by [11C]choline PET/CT: validation with surgical specimens. Eur J Nucl Med Mol Imaging 40:824–831CrossRefPubMed Bundschuh RA, Wendl CM, Weirich G et al (2013) Tumour volume delineation in prostate cancer assessed by [11C]choline PET/CT: validation with surgical specimens. Eur J Nucl Med Mol Imaging 40:824–831CrossRefPubMed
14.
Zurück zum Zitat Chatalic KL, Franssen GM, Van Weerden WM et al (2014) Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer. J Nucl Med 55:2050–2056CrossRefPubMed Chatalic KL, Franssen GM, Van Weerden WM et al (2014) Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer. J Nucl Med 55:2050–2056CrossRefPubMed
15.
Zurück zum Zitat Couture F, Levesque C, Dumulon-Perreault V et al (2014) PACE4-based molecular targeting of prostate cancer using an engineered (6)(4)Cu-radiolabeled peptide inhibitor. Neoplasia 16:634–643PubMedCentralCrossRefPubMed Couture F, Levesque C, Dumulon-Perreault V et al (2014) PACE4-based molecular targeting of prostate cancer using an engineered (6)(4)Cu-radiolabeled peptide inhibitor. Neoplasia 16:634–643PubMedCentralCrossRefPubMed
16.
Zurück zum Zitat De Santis M, Becherer A, Bokemeyer C et al (2004) 2–18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 22:1034–1039CrossRef De Santis M, Becherer A, Bokemeyer C et al (2004) 2–18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 22:1034–1039CrossRef
17.
Zurück zum Zitat De Santis M, Pont J (2004) The role of positron emission tomography in germ cell cancer. World J Urol 22:41–46CrossRef De Santis M, Pont J (2004) The role of positron emission tomography in germ cell cancer. World J Urol 22:41–46CrossRef
18.
Zurück zum Zitat Divgi CR, Uzzo RG, Gatsonis C et al (2013) Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J Clin Oncol 31:187–194CrossRefPubMed Divgi CR, Uzzo RG, Gatsonis C et al (2013) Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J Clin Oncol 31:187–194CrossRefPubMed
19.
Zurück zum Zitat Dusing RW, Peng W, Lai SM et al (2014) Prostate-specific antigen and prostate-specific antigen velocity as threshold indicators in 11C-acetate PET/CTAC scanning for prostate cancer recurrence. Clin Nucl Med 39:777–783PubMedCentralCrossRefPubMed Dusing RW, Peng W, Lai SM et al (2014) Prostate-specific antigen and prostate-specific antigen velocity as threshold indicators in 11C-acetate PET/CTAC scanning for prostate cancer recurrence. Clin Nucl Med 39:777–783PubMedCentralCrossRefPubMed
20.
Zurück zum Zitat Eder M, Schafer M, Bauder-Wust U et al (2014) Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer. Prostate 74:659–668CrossRefPubMed Eder M, Schafer M, Bauder-Wust U et al (2014) Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer. Prostate 74:659–668CrossRefPubMed
21.
Zurück zum Zitat Eiber M, Maurer T, Souvatzoglou M et al (2015) Evaluation of hybrid 68Ga-PSMA-ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 56(5):668–674. pii: jnumed.115.154153 Eiber M, Maurer T, Souvatzoglou M et al (2015) Evaluation of hybrid 68Ga-PSMA-ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 56(5):668–674. pii: jnumed.115.154153
22.
Zurück zum Zitat Eiber M, Nekolla SG, Maurer T et al (2014) Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer. Abdom Imaging (Epub ahead of print) Eiber M, Nekolla SG, Maurer T et al (2014) Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer. Abdom Imaging (Epub ahead of print)
23.
Zurück zum Zitat Evangelista L, Cimitan M, Zattoni F et al (2015) Comparison between conventional imaging (abdominal-pelvic computed tomography and bone scan) and [F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- to high-risk prostate cancer: a retrospective analysis. Scand J Urol 3:1–9CrossRef Evangelista L, Cimitan M, Zattoni F et al (2015) Comparison between conventional imaging (abdominal-pelvic computed tomography and bone scan) and [F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- to high-risk prostate cancer: a retrospective analysis. Scand J Urol 3:1–9CrossRef
24.
Zurück zum Zitat Evangelista L, Guttilla A, Zattoni F et al (2013) Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis. Eur Urol 63:1040–1048CrossRefPubMed Evangelista L, Guttilla A, Zattoni F et al (2013) Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis. Eur Urol 63:1040–1048CrossRefPubMed
25.
Zurück zum Zitat Giovacchini G, Incerti E, Mapelli P et al (2015) [C]Choline PET/CT predicts survival in hormone-naive prostate cancer patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 42(6):877–884CrossRefPubMed Giovacchini G, Incerti E, Mapelli P et al (2015) [C]Choline PET/CT predicts survival in hormone-naive prostate cancer patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 42(6):877–884CrossRefPubMed
26.
Zurück zum Zitat Giovacchini G, Picchio M, Garcia-Parra R et al (2014) 11C-choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen-deprivation therapy. J Nucl Med 55:233–241CrossRefPubMed Giovacchini G, Picchio M, Garcia-Parra R et al (2014) 11C-choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen-deprivation therapy. J Nucl Med 55:233–241CrossRefPubMed
27.
Zurück zum Zitat Golan S, Sopov V, Baniel J et al (2011) Comparison of 11C-choline with 18F-FDG in positron emission tomography/computerized tomography for staging urothelial carcinoma: a prospective study. J Urol 186:436–441CrossRefPubMed Golan S, Sopov V, Baniel J et al (2011) Comparison of 11C-choline with 18F-FDG in positron emission tomography/computerized tomography for staging urothelial carcinoma: a prospective study. J Urol 186:436–441CrossRefPubMed
28.
Zurück zum Zitat Goodfellow H, Viney Z, Hughes P et al (2014) Role of fluorodeoxyglucose positron emission tomography (FDG PET)-computed tomography (CT) in the staging of bladder cancer. BJU Int 114:389–395PubMed Goodfellow H, Viney Z, Hughes P et al (2014) Role of fluorodeoxyglucose positron emission tomography (FDG PET)-computed tomography (CT) in the staging of bladder cancer. BJU Int 114:389–395PubMed
29.
Zurück zum Zitat Graziani T, Ceci F, Lopes FL et al (2015) 11C-choline PET/CT for restaging of bladder cancer. Clin Nucl Med 40:1–5CrossRef Graziani T, Ceci F, Lopes FL et al (2015) 11C-choline PET/CT for restaging of bladder cancer. Clin Nucl Med 40:1–5CrossRef
30.
Zurück zum Zitat Heck MM, Souvatzoglou M, Retz M et al (2014) Prospective comparison of computed tomography, diffusion-weighted magnetic resonance imaging and [11C]choline positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer patients. Eur J Nucl Med Mol Imaging 41:694–701CrossRefPubMed Heck MM, Souvatzoglou M, Retz M et al (2014) Prospective comparison of computed tomography, diffusion-weighted magnetic resonance imaging and [11C]choline positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer patients. Eur J Nucl Med Mol Imaging 41:694–701CrossRefPubMed
31.
Zurück zum Zitat Hitier-Berthault M, Ansquer C, Branchereau J et al (2013) 18F-fluorodeoxyglucose positron emission tomography-computed tomography for preoperative lymph node staging in patients undergoing radical cystectomy for bladder cancer: a prospective study. Int J Urol 20:788–796CrossRefPubMed Hitier-Berthault M, Ansquer C, Branchereau J et al (2013) 18F-fluorodeoxyglucose positron emission tomography-computed tomography for preoperative lymph node staging in patients undergoing radical cystectomy for bladder cancer: a prospective study. Int J Urol 20:788–796CrossRefPubMed
32.
Zurück zum Zitat Huddart RA, O’doherty MJ, Padhani A et al (2007) 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22 – the NCRI Testis Tumour Clinical Study Group. J Clin Oncol 25:3090–3095CrossRefPubMed Huddart RA, O’doherty MJ, Padhani A et al (2007) 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22 – the NCRI Testis Tumour Clinical Study Group. J Clin Oncol 25:3090–3095CrossRefPubMed
33.
Zurück zum Zitat Israel I, Richter D, Stritzker J et al (2014) PET imaging with [(6)(8)Ga]NOTA-RGD for prostate cancer: a comparative study with [(1)(8)F]fluorodeoxyglucose and [(1)(8)F]fluoroethylcholine. Curr Cancer Drug Targets 14:371–379CrossRefPubMed Israel I, Richter D, Stritzker J et al (2014) PET imaging with [(6)(8)Ga]NOTA-RGD for prostate cancer: a comparative study with [(1)(8)F]fluorodeoxyglucose and [(1)(8)F]fluoroethylcholine. Curr Cancer Drug Targets 14:371–379CrossRefPubMed
34.
Zurück zum Zitat Jeong IG, Hong S, You D et al (2015) FDG PET-CT for lymph node staging of bladder cancer: a prospective study of patients with extended pelvic lymphadenectomy. Ann Surg Oncol (Epub ahead of print) Jeong IG, Hong S, You D et al (2015) FDG PET-CT for lymph node staging of bladder cancer: a prospective study of patients with extended pelvic lymphadenectomy. Ann Surg Oncol (Epub ahead of print)
35.
Zurück zum Zitat Kahkonen E, Jambor I, Kemppainen J et al (2013) In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548. Clin Cancer Res19:5434–5443CrossRef Kahkonen E, Jambor I, Kemppainen J et al (2013) In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548. Clin Cancer Res19:5434–5443CrossRef
36.
Zurück zum Zitat Kibel AS, Dehdashti F, Katz MD et al (2009) Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol 27:4314–4320PubMedCentralCrossRefPubMed Kibel AS, Dehdashti F, Katz MD et al (2009) Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol 27:4314–4320PubMedCentralCrossRefPubMed
37.
Zurück zum Zitat Kjolhede H, Ahlgren G, Almquist H et al (2014) (1)(8)F-fluorocholine PET/CT compared with extended pelvic lymph node dissection in high-risk prostate cancer. World J Urol 32:965–970CrossRefPubMed Kjolhede H, Ahlgren G, Almquist H et al (2014) (1)(8)F-fluorocholine PET/CT compared with extended pelvic lymph node dissection in high-risk prostate cancer. World J Urol 32:965–970CrossRefPubMed
38.
Zurück zum Zitat Knowles SM, Tavare R, Zettlitz KA et al (2014) Applications of immunoPET: using 124I-anti-PSCA A11 minibody for imaging disease progression and response to therapy in mouse xenograft models of prostate cancer. Clin Cancer Res 20:6367–6378CrossRefPubMed Knowles SM, Tavare R, Zettlitz KA et al (2014) Applications of immunoPET: using 124I-anti-PSCA A11 minibody for imaging disease progression and response to therapy in mouse xenograft models of prostate cancer. Clin Cancer Res 20:6367–6378CrossRefPubMed
39.
Zurück zum Zitat Kollberg P, Almquist H, Blackberg M et al (2015) [F]Fluorodeoxyglucose – positron emission tomography/computed tomography improves staging in patients with high-risk muscle-invasive bladder cancer scheduled for radical cystectomy. Scand J Urol 26:1–6CrossRef Kollberg P, Almquist H, Blackberg M et al (2015) [F]Fluorodeoxyglucose – positron emission tomography/computed tomography improves staging in patients with high-risk muscle-invasive bladder cancer scheduled for radical cystectomy. Scand J Urol 26:1–6CrossRef
40.
Zurück zum Zitat Krause BJ, Souvatzoglou M, Tuncel M et al (2008) The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 35:18–23CrossRefPubMed Krause BJ, Souvatzoglou M, Tuncel M et al (2008) The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 35:18–23CrossRefPubMed
41.
Zurück zum Zitat Lesche R, Kettschau G, Gromov AV et al (2014) Preclinical evaluation of BAY 1075553, a novel (18)F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging 41:89–101CrossRefPubMed Lesche R, Kettschau G, Gromov AV et al (2014) Preclinical evaluation of BAY 1075553, a novel (18)F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging 41:89–101CrossRefPubMed
42.
Zurück zum Zitat Maurer T, Beer AJ, Wester HJ et al (2014) Positron emission tomography/magnetic resonance imaging with 68Gallium-labeled ligand of prostate-specific membrane antigen: promising novel option in prostate cancer imaging? Int J Urol 21:1286–1288CrossRefPubMed Maurer T, Beer AJ, Wester HJ et al (2014) Positron emission tomography/magnetic resonance imaging with 68Gallium-labeled ligand of prostate-specific membrane antigen: promising novel option in prostate cancer imaging? Int J Urol 21:1286–1288CrossRefPubMed
43.
Zurück zum Zitat Maurer T, Gschwend JE, Wester H-J et al (2015) PET imaging with of prostate-specific membrane antigen (PSMA) for staging of primary prostate cancer with 68Ga-HBED-PSMA. ASCO Annual Meeting, Chicago Maurer T, Gschwend JE, Wester H-J et al (2015) PET imaging with of prostate-specific membrane antigen (PSMA) for staging of primary prostate cancer with 68Ga-HBED-PSMA. ASCO Annual Meeting, Chicago
44.
Zurück zum Zitat Maurer T, Horn T, Souvatzoglou M et al (2014) Prognostic value of 11C-choline PET/CT and CT for predicting survival of bladder cancer patients treated with radical cystectomy. Urol Int 93:207–213CrossRefPubMed Maurer T, Horn T, Souvatzoglou M et al (2014) Prognostic value of 11C-choline PET/CT and CT for predicting survival of bladder cancer patients treated with radical cystectomy. Urol Int 93:207–213CrossRefPubMed
45.
Zurück zum Zitat Maurer T, Souvatzoglou M, Kubler H et al (2012) Diagnostic efficacy of [11C]choline positron emission tomography/computed tomography compared with conventional computed tomography in lymph node staging of patients with bladder cancer prior to radical cystectomy. Eur Urol 61:1031–1038CrossRefPubMed Maurer T, Souvatzoglou M, Kubler H et al (2012) Diagnostic efficacy of [11C]choline positron emission tomography/computed tomography compared with conventional computed tomography in lymph node staging of patients with bladder cancer prior to radical cystectomy. Eur Urol 61:1031–1038CrossRefPubMed
46.
Zurück zum Zitat Maurer T, Weirich G, Schottelius M et al (2015) Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer. Eur Urol (Epub ahead of print). pii: S0302-2838(15)00376-0. doi: 10.1016/j.eururo.2015.04.034 Maurer T, Weirich G, Schottelius M et al (2015) Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer. Eur Urol (Epub ahead of print). pii: S0302-2838(15)00376-0. doi: 10.1016/j.eururo.2015.04.034
47.
48.
Zurück zum Zitat Mertens LS, Fioole-Bruining A, Vegt E et al (2013) Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle. BJU Int 112:729–734CrossRefPubMed Mertens LS, Fioole-Bruining A, Vegt E et al (2013) Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle. BJU Int 112:729–734CrossRefPubMed
49.
Zurück zum Zitat Mertens LS, Mir MC, Scott AM et al (2014) 18F-fluorodeoxyglucose – positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer. Urology 83:393–398CrossRefPubMed Mertens LS, Mir MC, Scott AM et al (2014) 18F-fluorodeoxyglucose – positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer. Urology 83:393–398CrossRefPubMed
50.
Zurück zum Zitat Mohsen B, Giorgio T, Rasoul ZS et al (2013) Application of C-11-acetate positron-emission tomography (PET) imaging in prostate cancer: systematic review and meta-analysis of the literature. BJU Int 112:1062–1072CrossRefPubMed Mohsen B, Giorgio T, Rasoul ZS et al (2013) Application of C-11-acetate positron-emission tomography (PET) imaging in prostate cancer: systematic review and meta-analysis of the literature. BJU Int 112:1062–1072CrossRefPubMed
51.
Zurück zum Zitat Namura K, Minamimoto R, Yao M et al (2010) Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report. BMC Cancer 10:667PubMedCentralCrossRefPubMed Namura K, Minamimoto R, Yao M et al (2010) Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report. BMC Cancer 10:667PubMedCentralCrossRefPubMed
52.
Zurück zum Zitat Nanni C, Schiavina R, Brunocilla E et al (2014) 18F-FACBC compared with 11C-choline PET/CT in patients with biochemical relapse after radical prostatectomy: a prospective study in 28 patients. Clin Genitourin Cancer 12:106–110CrossRefPubMed Nanni C, Schiavina R, Brunocilla E et al (2014) 18F-FACBC compared with 11C-choline PET/CT in patients with biochemical relapse after radical prostatectomy: a prospective study in 28 patients. Clin Genitourin Cancer 12:106–110CrossRefPubMed
53.
Zurück zum Zitat Oechsle K, Hartmann M, Brenner W et al (2008) [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group. J Clin Oncol 26:5930–5935CrossRefPubMed Oechsle K, Hartmann M, Brenner W et al (2008) [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group. J Clin Oncol 26:5930–5935CrossRefPubMed
54.
Zurück zum Zitat Orevi M, Klein M, Mishani E et al (2012) 11C-acetate PET/CT in bladder urothelial carcinoma: intraindividual comparison with 11C-choline. Clin Nucl Med 37:67–72CrossRef Orevi M, Klein M, Mishani E et al (2012) 11C-acetate PET/CT in bladder urothelial carcinoma: intraindividual comparison with 11C-choline. Clin Nucl Med 37:67–72CrossRef
55.
Zurück zum Zitat Pan D, Yan Y, Yang R et al (2014) PET imaging of prostate tumors with 18F-Al-NOTA-MATBBN. Contrast Media Mol Imaging 9:342–348CrossRefPubMed Pan D, Yan Y, Yang R et al (2014) PET imaging of prostate tumors with 18F-Al-NOTA-MATBBN. Contrast Media Mol Imaging 9:342–348CrossRefPubMed
56.
Zurück zum Zitat Pandit-Taskar N, O’donoghue JA, Beylergil V et al (2014) (8)(9)Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. Eur J Nucl Med Mol Imaging 41:2093–2105PubMedCentralCrossRefPubMed Pandit-Taskar N, O’donoghue JA, Beylergil V et al (2014) (8)(9)Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. Eur J Nucl Med Mol Imaging 41:2093–2105PubMedCentralCrossRefPubMed
57.
Zurück zum Zitat Park JW, Jo MK, Lee HM (2009) Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma. BJU Int 103:615–619CrossRefPubMed Park JW, Jo MK, Lee HM (2009) Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma. BJU Int 103:615–619CrossRefPubMed
58.
Zurück zum Zitat Revheim ME, Winge-Main AK, Hagen G et al (2011) Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma. Clin Oncol (R Coll Radiol) 23:339–343 Revheim ME, Winge-Main AK, Hagen G et al (2011) Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma. Clin Oncol (R Coll Radiol) 23:339–343
59.
Zurück zum Zitat Richter S, Wuest M, Krieger SS et al (2013) Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer. Nucl Med Biol 40:1025–1034CrossRefPubMed Richter S, Wuest M, Krieger SS et al (2013) Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer. Nucl Med Biol 40:1025–1034CrossRefPubMed
60.
Zurück zum Zitat Rodado-Marina S, Coronado-Poggio M, Garcia-Vicente AM et al (2014) Clinical utility of F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study. BJU Int (Epub ahead of print) Rodado-Marina S, Coronado-Poggio M, Garcia-Vicente AM et al (2014) Clinical utility of F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study. BJU Int (Epub ahead of print)
61.
Zurück zum Zitat Sah BR, Burger IA, Schibli R et al (2015) Dosimetry and first clinical evaluation of the new 18F-radiolabeled bombesin analogue BAY 864367 in patients with prostate cancer. J Nucl Med 56:372–378CrossRefPubMed Sah BR, Burger IA, Schibli R et al (2015) Dosimetry and first clinical evaluation of the new 18F-radiolabeled bombesin analogue BAY 864367 in patients with prostate cancer. J Nucl Med 56:372–378CrossRefPubMed
62.
Zurück zum Zitat Schoder H, Ong SC, Reuter VE et al (2012) Initial results with (11)C-acetate positron emission tomography/computed tomography (PET/CT) in the staging of urinary bladder cancer. Mol Imaging Biol 14:245–251CrossRefPubMed Schoder H, Ong SC, Reuter VE et al (2012) Initial results with (11)C-acetate positron emission tomography/computed tomography (PET/CT) in the staging of urinary bladder cancer. Mol Imaging Biol 14:245–251CrossRefPubMed
63.
Zurück zum Zitat Schumacher MC, Radecka E, Hellstrom M et al (2015) [11C]Acetate positron emission tomography-computed tomography imaging of prostate cancer lymph-node metastases correlated with histopathological findings after extended lymphadenectomy. Scand J Urol 49:35–42CrossRefPubMed Schumacher MC, Radecka E, Hellstrom M et al (2015) [11C]Acetate positron emission tomography-computed tomography imaging of prostate cancer lymph-node metastases correlated with histopathological findings after extended lymphadenectomy. Scand J Urol 49:35–42CrossRefPubMed
64.
Zurück zum Zitat Souvatzoglou M, Weirich G, Schwarzenboeck S et al (2011) The sensitivity of [11C]choline PET/CT to localize prostate cancer depends on the tumor configuration. Clin Cancer Res 17:3751–3759CrossRefPubMed Souvatzoglou M, Weirich G, Schwarzenboeck S et al (2011) The sensitivity of [11C]choline PET/CT to localize prostate cancer depends on the tumor configuration. Clin Cancer Res 17:3751–3759CrossRefPubMed
65.
Zurück zum Zitat Storz E, Shah A, Zettinig O et al (2015) PSMA-PET/MRI-guided transrectal fusion biopsy for the detection of prostate cancer. EAU Annual Meeting, Madrid Storz E, Shah A, Zettinig O et al (2015) PSMA-PET/MRI-guided transrectal fusion biopsy for the detection of prostate cancer. EAU Annual Meeting, Madrid
66.
Zurück zum Zitat Sweat SD, Pacelli A, Murphy GP et al (1998) Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 52:637–640CrossRefPubMed Sweat SD, Pacelli A, Murphy GP et al (1998) Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 52:637–640CrossRefPubMed
67.
Zurück zum Zitat Swinnen G, Maes A, Pottel H et al (2010) FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. Eur Urol 57:641–647CrossRefPubMed Swinnen G, Maes A, Pottel H et al (2010) FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. Eur Urol 57:641–647CrossRefPubMed
68.
Zurück zum Zitat Turkbey B, Mena E, Shih J et al (2014) Localized prostate cancer detection with 18F FACBC PET/CT: comparison with MR imaging and histopathologic analysis. Radiology 270:849–856PubMedCentralCrossRefPubMed Turkbey B, Mena E, Shih J et al (2014) Localized prostate cancer detection with 18F FACBC PET/CT: comparison with MR imaging and histopathologic analysis. Radiology 270:849–856PubMedCentralCrossRefPubMed
69.
Zurück zum Zitat Ueno D, Yao M, Tateishi U et al (2012) Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course. BMC Cancer 12:162PubMedCentralCrossRefPubMed Ueno D, Yao M, Tateishi U et al (2012) Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course. BMC Cancer 12:162PubMedCentralCrossRefPubMed
70.
Zurück zum Zitat Vag T, Heck MM, Beer AJ et al (2014) Preoperative lymph node staging in patients with primary prostate cancer: comparison and correlation of quantitative imaging parameters in diffusion-weighted imaging and 11C-choline PET/CT. Eur Radiol 24:1821–1826CrossRefPubMed Vag T, Heck MM, Beer AJ et al (2014) Preoperative lymph node staging in patients with primary prostate cancer: comparison and correlation of quantitative imaging parameters in diffusion-weighted imaging and 11C-choline PET/CT. Eur Radiol 24:1821–1826CrossRefPubMed
71.
Zurück zum Zitat Vercellino L, Bousquet G, Baillet G et al (2009) 18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study. Cancer Biother Radiopharm 24:137–144CrossRefPubMed Vercellino L, Bousquet G, Baillet G et al (2009) 18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study. Cancer Biother Radiopharm 24:137–144CrossRefPubMed
72.
Zurück zum Zitat Viola-Villegas NT, Sevak KK, Carlin SD et al (2014) Noninvasive Imaging of PSMA in prostate tumors with (89)Zr-Labeled huJ591 engineered antibody fragments: the faster alternatives. Mol Pharm 11:3965–3973PubMedCentralCrossRefPubMed Viola-Villegas NT, Sevak KK, Carlin SD et al (2014) Noninvasive Imaging of PSMA in prostate tumors with (89)Zr-Labeled huJ591 engineered antibody fragments: the faster alternatives. Mol Pharm 11:3965–3973PubMedCentralCrossRefPubMed
73.
Zurück zum Zitat Wang HY, Ding HJ, Chen JH et al (2012) Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET/CT in renal cell carcinoma. Cancer Imaging 12:464–474PubMedCentralCrossRefPubMed Wang HY, Ding HJ, Chen JH et al (2012) Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET/CT in renal cell carcinoma. Cancer Imaging 12:464–474PubMedCentralCrossRefPubMed
74.
Zurück zum Zitat Wetter A, Nensa F, Schenck M et al (2014) Combined PET imaging and diffusion-weighted imaging of intermediate and high-risk primary prostate carcinomas with simultaneous [18F] choline PET/MRI. PLoS One 9:101571CrossRef Wetter A, Nensa F, Schenck M et al (2014) Combined PET imaging and diffusion-weighted imaging of intermediate and high-risk primary prostate carcinomas with simultaneous [18F] choline PET/MRI. PLoS One 9:101571CrossRef
75.
Zurück zum Zitat Wieser G, Mansi R, Grosu AL et al (2014) Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist – from mice to men. Theranostics 4:412–419PubMedCentralCrossRefPubMed Wieser G, Mansi R, Grosu AL et al (2014) Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist – from mice to men. Theranostics 4:412–419PubMedCentralCrossRefPubMed
76.
Zurück zum Zitat Yu CY, Desai B, Ji L et al (2014) Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature. Am J Nucl Med Mol Imaging 4:580–601PubMedCentralPubMed Yu CY, Desai B, Ji L et al (2014) Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature. Am J Nucl Med Mol Imaging 4:580–601PubMedCentralPubMed
Metadaten
Titel
Positronenemissionstomographie bei urologischen Tumorerkrankungen
verfasst von
PD Dr. T. Maurer
H. Kübler
J.E. Gschwend
M. Eiber
Publikationsdatum
01.07.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Die Urologie / Ausgabe 7/2015
Print ISSN: 2731-7064
Elektronische ISSN: 2731-7072
DOI
https://doi.org/10.1007/s00120-015-3868-2

Weitere Artikel der Ausgabe 7/2015

Der Urologe 7/2015 Zur Ausgabe

Berufspolitik BDU

Berufspolitik BDU

URO-Telegramm

Uro-Telegramm

Einführung zum Thema

Bildgebung in der Urologie

Passend zum Thema

ANZEIGE

Bei Immuntherapien das erhöhte Thromboserisiko beachten

Unter modernen Systemtherapien versechsfacht sich das VTE-Risiko. Warum diese Daten relevant für die Behandlung krebsassoziierter Thrombosen sind, erläutert Prof. F. Langer im Interview. So kann es durch Immuntherapien zu inflammatorischen Syndromen z.B. im GI-Trakt kommen. Nebenwirkungen wie Durchfall oder Mukositis haben dann Einfluss auf die Wirksamkeit oraler Antikoagulantien. Aber auch in punkto Blutungsrisiko ist Vorsicht geboten. Wann hier bevorzugt NMH eingesetzt werden sollten, erläutert Prof. Langer im Interview.

ANZEIGE

CAT-Management ist ganz einfach – oder doch nicht?

Krebsassoziierte venöse Thromboembolien (CAT) haben in den vergangenen Jahren stetig zugenommen. Was hat der Anstieg mit modernen Antitumortherapien zu tun? Venöse Thromboembolien sind relevante Morbiditäts- und Mortalitätsfaktoren in der Onkologie. Besonders hoch sind die Risiken bei Tumoren des Abdominalraums. Eine antithrombotische Primärprophylaxe ist daher gerade bei gastrointestinalen (GI-) Tumoren auch im ambulanten Setting wichtig.

ANZEIGE

Management von Thromboembolien bei Krebspatienten

Die Thromboembolie ist neben Infektionen die zweithäufigste Todesursache bei Krebspatienten. Die Behandlung der CAT (cancer associated thrombosis) ist komplex und orientiert sich am individuellen Patienten. Angesichts einer Vielzahl zur Verfügung stehender medikamentöser Behandlungsoptionen finden Sie hier Video-Experteninterviews, Sonderpublikationen und aktuelle Behandlungsalgorithmen zur Therapieentscheidung auf Basis von Expertenempfehlungen.

LEO Pharma GmbH